Following these proceedings, Piper Sandler initiated its Unicycive Therapeutics Inc [UNCY] rating to an Overweight in a research note published on April 04, 2024; the price target was $9.
Price Performance Review of UNCY
On Tuesday, Unicycive Therapeutics Inc [NASDAQ:UNCY] saw its stock jump 2.41% to $0.78. Over the last five days, the stock has lost -4.11%. Unicycive Therapeutics Inc shares have fallen nearly -2.06% since the year began. Nevertheless, the stocks have fallen -7.40% over the past one year. While a 52-week high of $1.82 was reached on 01/03/25, a 52-week low of $0.20 was recorded on 01/07/25. SMA at 50 days reached $0.6287, while 200 days put it at $0.6671.
Levels Of Support And Resistance For UNCY Stock
The 24-hour chart illustrates a support level at 0.7152, which if violated will result in even more drops to 0.6526. On the upside, there is a resistance level at 0.8152. A further resistance level may holdings at 0.8526. The Relative Strength Index (RSI) on the 14-day chart is 60.01, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0301, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 26.11%. Stochastics %K at 72.02% indicates the stock is a holding.
How much short interest is there in Unicycive Therapeutics Inc?
A steep rise in short interest was recorded in Unicycive Therapeutics Inc stocks on 2024-10-31, growing by 60323.0 shares to a total of 1.05 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 0.99 million shares. There was a rise of 5.72%, which implies that there is a positive sentiment for the stock.
